Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 3/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764324 | 0.84 | CRBN (0.61) | CRBNBRPF1TDP2PIP4K2APIP4K2B | |
| SCHEMBL1764553 | 0.83 | CRBN (0.59) | CRBNBRPF1TDP2BRD4ABL1 | |
| SCHEMBL12595095 | 0.78 | HSD17B1 (0.36) | CRBNBRPF1TDP2PIP4K2APIP4K2B | |
| SCHEMBL1530231 | 0.73 | CRBN (0.66) | CRBNBRPF1TDP2PIP4K2APIP4K2B | |
| SCHEMBL12840935 | 0.72 | CRBN (0.56) | CRBNBRPF1TDP2PIP4K2APIP4K2B | |
| SCHEMBL14865412 | 0.71 | CRBN (0.44) | CRBNBRPF1TDP2PIP4K2APIP4K2B | |
| SCHEMBL17378874 | 0.70 | CRBN (0.59) | CRBNBRPF1BRD4ALDH1A1ABL1 | |
| SCHEMBL2111449 | 0.70 | CYP3A4 (0.41) | CRBN | |
| SCHEMBL2111450 | 0.70 | CYP3A4 (0.41) | CRBN | |
| SCHEMBL1530347 | 0.69 | CRBN (0.79) | CRBNBRPF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513092-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | claimed |
| WO-2011073114-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | claimed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | claimed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RRM2B, POLR2A, RRM2 | CRBN 1400/4885BRPF1 3090/4885TDP2 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.